医学
内科学
肥胖
外科
兴奋剂
减肥
多中心研究
受体
胃肠病学
临床试验
糖尿病
胰高血糖素样肽1受体
体质指数
队列研究
梅德林
作者
Ahmed Mahmoud,Kamal Awad,Hesham Sheashaa,Omneya Kandil,Juan Farina,Ramzi Ibrahim,Mahmoud Abdelnabi,Mohamed Allam,Rohit Mital,Justin N. Shipman,Said Alsidawi,Steven J. Lester,Steve R. Ommen,Jeffrey Benjamin Geske,Richard D. Patten,Chadi Ayoub,Reza Arsanjani
标识
DOI:10.1093/ehjqcco/qcag051
摘要
AIMS: Obesity is linked with worse outcomes in hypertrophic cardiomyopathy (HCM). While both bariatric surgery (BS) and GLP-1 receptor agonists (GLP-1RA) promote weight loss and may improve cardiometabolic risk, their comparative outcomes in HCM remain unclear. METHODS AND RESULTS: Adults with HCM and body mass index (BMI) ≥ 30 kg/m were divided into two cohorts: (i) GLP-1 RA users who never had BS, and (ii) BS patients who never received GLP-1 RA. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and medications. Outcomes over 24 months include all-cause mortality, acute heart failure (HF) hospitalization, arrhythmias, change in BMI, and cardiovascular symptoms. Hazard ratios with 95% confidence intervals were estimated using Cox models. Of 5002 patients, 955 were included in each matched cohort after matching (mean age 54 ± 13 years, 70% female, BMI 40.0 kg/m). GLP-1 RA was associated with a significantly lower observed rate of all-cause mortality compared with BS (2.0% vs. 4.4%; HR 0.46; 95% CI 0.27-0.80; P = 0.004) and HF hospitalization (8.7% vs. 14.0%; HR 0.60; 95% CI 0.46-0.79; P < 0.001). Similarly, GLP-1 RA use was associated with a lower incidence of composite cardiovascular outcomes (10.7% vs. 17.2%; HR 0.60; 95% CI 0.47-0.77; P < 0.001). Rates of arrhythmia and cardiovascular symptoms were comparable between the two groups. BMI reduction was greater after bariatric surgery (-4.0 vs. -2.6 kg/m; P < 0.001). CONCLUSION: In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI